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Background: At least 4 grams of prescription omega-3 ethyl esters (EE) are required to lower non-high density lipoprotein cholesterol (non-
HDL-c) in patients treated with a statin with triglycerides (TG) between 200-499 mg/dL. Omega-3 EE require hydrolysis to free-fatty acids (FFA) 
by pancreatic lipases for absorption. Epanova, a novel omega-3 FFA does not require hydrolysis and has been shown to have up to 5-fold greater 
bioavailability (BA) than the EE form. This improvement in BA may lead to a lower daily dosage compared to EE formulations. The ESPRIT trial 
evaluated a 2 g/d dosage as well as a 4 g/d of Epanova compared to olive oil (OO) in patients with persistent high TG (HTG) and high risk for 
cardiovascular disease.
methods: A total of 647 diet-stable patients with fasting TG ≥ 200 mg/dl and < 500 mg/dl (who were on a maximally tolerated dose of statin or 
statin/ezetimbe therapy) were randomized to Epanova 2 g/d, 4 g/d, or OO in this 6 week double-blind study. The primary efficacy endpoint for each 
arm was the percent change in non-HDL-C from baseline to end-of-treatment.
results: 
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Non-HDL-C 131.7 -0.9 139.0 -3.9 0.0373 134.7 -6.9 <0.0001
TG 269.0 -5.9 265.0 -14.6 <0.0001 265.3 -20.6 <0.0001
HDL-C 37.7 2.2 37.7 2.6 0.9881 36.7 3.3 0.9881
LDL-C 87.0 1.1 92.0 4.6 0.0247 91.0 1.3 0.6470
VLDL-C 42.0 -5.9 42.0 -14.3 0.0082 43.0 -21.5 <0.0001
Apo B 92.0 0.3 94.0 0.7 0.5272 93.5 -2.1 0.0352
ApoC-III 15.0 -3.2 15.0 -7.6 0.0655 15.0 -13.1 <0.0001
Lp-PLA2 209.0 0.1 214.0 -6.2 0.0002 209.0 -10.7 <0.0001
Withdrawals related to treatment emergent adverse events were 1.9% overall. Non-HDL-c reduction was greater in patients on high potency statins 
compared to low potency statins and in patients with higher baseline non-HDL-c, TG and/or ApoC-III levels.
conclusion: Omega-3 FFA at a low 2 g/d dosage is effective and well tolerated for lowering of non-HDL-C, TG, and other markers of cardiovascular 
risk in patients with persistent HTG on a statin.
